Ken Griffin Sarepta Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 127,800 shares of SRPT stock, worth $12.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127,800
Previous 308,000
58.51%
Holding current value
$12.9 Million
Previous $38.5 Million
59.61%
% of portfolio
0.0%
Previous 0.01%
Shares
30 transactions
Others Institutions Holding SRPT
# of Institutions
535Shares Held
87.4MCall Options Held
1.55MPut Options Held
1.35M-
Black Rock Inc. New York, NY10.3MShares$1.05 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$920 Million0.02% of portfolio
-
Capital International Investors Los Angeles, CA8.7MShares$880 Million0.21% of portfolio
-
Janus Henderson Group PLC London, X04.33MShares$438 Million0.28% of portfolio
-
State Street Corp Boston, MA4.07MShares$412 Million0.02% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $8.86B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...